Business
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
LYON, France, November 24, 2025--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), provides an update on its proposed recovery plan and announces the organisation of a webinar.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/d0d24a916045adbb03bdb96bcaffdc31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KLXyBlvAUDBaO.v0vyqpTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d0d24a916045adbb03bdb96bcaffdc31","width":480,"height":256}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Poxel's recovery plan has been finalised:","length":45,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Main objectives:","length":16,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"accelerating commercial development and partnership-seeking activities for Imeglimine outside Japan, PXL 770 and PXL 065,","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"significantly reducing the Company's costs, and","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"clearing the Company's liabilities.","length":39,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":211,"olType":false}]},{"val":[{"type":"text","content":"It was developed with the support of its long-standing financial partner IPF.","length":77,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IPF and IRIS have committed to providing the Company with new financing of up to €11.25 million (including amounts drawn during the observation period) to turn it around.","length":170,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The draft plan remains subject to the decision of the Commercial Court (Tribunal des activités économiques) of Lyon.","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":590,"olType":false}]},{"val":[{"type":"text","content":"As a reminder, shareholders will meet at the annual general meeting on 11 December 2025 to approve, in particular:","length":114,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Poxel's 2024 annual and consolidated financial statements,","length":62,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"the listing of Poxel shares on Eurone...